London Health Sciences Centre Research Institute
London Health Sciences Centre Research Institute
London, Ontario, Canada8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Citalopram and the Risk of Serious Adverse Events | Chemically-Induced Disorders, Chronic Disease, Disease Attributes, Drug-Related Side Effects and Adverse Reactions, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07399795 | |
| Sertraline and the Risk of Serious Adverse Events | Chemically-Induced Disorders, Chronic Disease, Disease Attributes, Drug-Related Side Effects and Adverse Reactions, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07387120 | |
| Pramipexole and the Risk of Serious Adverse Events | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07382960 | |
| Escitalopram and the Risk of Serious Adverse Events | Chemically-Induced Disorders, Chronic Disease, Disease Attributes, Drug-Related Side Effects and Adverse Reactions, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07274241 | |
| Tamsulosin and the Risk of Serious Adverse Events | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07274228 | |
| Lorazepam and the Risk of Serious Adverse Events | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07179978 | |
| Domperidone and the Risk of Serious Adverse Events | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT07098078 | |
| Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Enrolling by invitation | Not stated | 2025-12-12 | NCT07100054 |